<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Maya Yazbek on Medium]]></title>
        <description><![CDATA[Stories by Maya Yazbek on Medium]]></description>
        <link>https://medium.com/@mayayazbek469?source=rss-deffa67e51c6------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*zdBlI_1e2LhX6Bd3</url>
            <title>Stories by Maya Yazbek on Medium</title>
            <link>https://medium.com/@mayayazbek469?source=rss-deffa67e51c6------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 05:41:14 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@mayayazbek469/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Can CRISPR Fix the Genetic Mutation Behind Cystic Fibrosis? Replicating a Published Study]]></title>
            <link>https://medium.com/@mayayazbek469/can-crispr-fix-the-genetic-mutation-behind-cystic-fibrosis-replicating-a-published-study-6fff681eb8eb?source=rss-deffa67e51c6------2</link>
            <guid isPermaLink="false">https://medium.com/p/6fff681eb8eb</guid>
            <category><![CDATA[gene-editing]]></category>
            <category><![CDATA[crispr]]></category>
            <category><![CDATA[cystic-fibrosis]]></category>
            <category><![CDATA[biotechnology]]></category>
            <dc:creator><![CDATA[Maya Yazbek]]></dc:creator>
            <pubDate>Sat, 07 Nov 2026 16:31:13 GMT</pubDate>
            <atom:updated>2026-11-07T16:31:13.926Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*MMQpN-cG9nY_oqDS0LvBJw.png" /><figcaption>credit:©istock, <a href="https://www.istockphoto.com/portfolio/magicmine?mediatype=photography">magicmine</a></figcaption></figure><p><strong>Taking My CRISPR Research Further <br></strong>For this project, I wanted to take my interest in CRISPR a step further by exploring how it is actually being used in scientific research. I decided to investigate cystic fibrosis, a genetic condition associated with mutations in the CFTR gene, focusing specifically on F508del, one of the most common disease-causing mutations.</p><p>I wanted to understand whether scientists could use CRISPR-Cas9 to correct this mutation and what the results of their experiments actually showed.</p><p>Instead of conducting a laboratory experiment myself, I chose to replicate parts of an existing scientific study. I explored the researchers’ experimental design, reconstructed their published results in a spreadsheet, and analysed which CRISPR approach performed best.</p><p>This project became more than just learning about gene editing. It challenged me to understand scientific research, interpret data, and distinguish between promising results and what they really mean.</p><p><strong>Finding a Real Study to Replicate<br></strong>To investigate this question, I chose a 2020 research paper by Smirnikhina and colleagues titled P.F508del editing in cells from cystic fibrosis patients, published in PLOS ONE.</p><p>I chose this study because it focused directly on the F508del mutation and explored how CRISPR-Cas9 could potentially correct it in cells from people with cystic fibrosis.</p><p>What made the paper particularly useful for my project was that it compared different CRISPR-Cas9 systems and guide RNA combinations. It also presented experimental results that I could record, organise, and analyse myself.</p><p>Rather than simply summarising the researchers’ conclusions, I wanted to work through parts of their study and see what I could learn from the data.</p><p><strong>Breaking Down the CRISPR Experiment<br></strong>When I first looked at the experimental design in the paper, I found it quite challenging to understand all the different components. The researchers compared several CRISPR-Cas9 combinations, including SpCas9, a modified version called SpCas9(HF4), and SaCas9.</p><p>Each system was paired with guide RNAs (sgRNAs), which help direct Cas9 to the intended DNA target.</p><p>The researchers also used repair templates called single-stranded oligodeoxynucleotides (ssODNs). These templates provided the DNA sequence needed to restore the missing three bases in the F508del mutation.</p><p>The goal was to use a cellular repair process called homology-directed repair (HDR) to introduce the intended correction after Cas9 made a cut in the DNA.</p><p>To understand the design, I studied Figure 1 of the paper and documented the different Cas9 systems, guide RNAs, and repair templates in my research notes.</p><p>This helped me understand that gene editing is not just about cutting DNA. The choice of editing system, guide RNA, and repair strategy all matter when trying to achieve a precise genetic correction.</p><p><strong>Turning Published Data Into My Own Analysis</strong><br>After understanding the experimental design, I moved on to the results. I wanted to go beyond simply reading the numbers in the paper, so I recreated the published data in a Google spreadsheet.</p><p>I organized the results into different CRISPR-Cas9 combinations and compared their reported HDR outcomes. I also recorded the precise HDR results to better understand how often the intended genetic correction was achieved.</p><p>One result that stood out to me was the combination of SpCas9(HF4) with sg#1, which showed the highest precise genomic HDR value in my comparison: 49.63% relative to NHEJ.</p><p>I visualised the results using a bar chart, making it easier to compare the different combinations and identify which performed best.</p><p>However, one important detail I learned was that this 49.63% does not mean that 49.63% of all cells were successfully corrected. It represents the ratio of precise HDR events to NHEJ events. The distinction matters because the overall correction frequency was much lower.</p><p>Recreating the data helped me understand the importance of looking beyond the highest number and asking what that number actually represents.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/896/1*dbChB0bERwvfW4KlXEyuRg.png" /><figcaption>Figure 1. Recreated dataset comparing HDR outcomes across the CRISPR-Cas9 combinations reported in the study.</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/600/1*34lQP_uxhB9Q7idecedJGg.png" /><figcaption>Figure 2. Comparison of precise genomic HDR outcomes, highlighting SpCas9(HF4) + sg#1 as the highest-performing combination.</figcaption></figure><p><strong>The Difference Between a Promising Result and a Real Solution<br></strong>At first, seeing a precise genomic HDR value of 49.63% seemed incredibly promising. However, as I looked more closely at the paper, I realised that this number didn’t tell the whole story.</p><p>The 49.63% value represented the ratio of precise HDR events to NHEJ events, rather than the percentage of all cells that had been successfully corrected.</p><p>The paper also reported much lower overall HDR frequencies: 1.42% in CFTE29o cells and 2.38% in patient-derived induced pluripotent stem cells (iPSCs).</p><p>This was one of the biggest lessons I took from the project: a result can look impressive when viewed in isolation, but its meaning changes when you understand how it was calculated.</p><p>Although the researchers demonstrated that CRISPR-Cas9 could introduce the intended correction, the overall editing efficiency remained a major limitation.</p><p>This means the findings are promising, but they do not demonstrate a cure for cystic fibrosis. More research is needed to improve editing efficiency and investigate whether the approach could eventually be useful as a treatment.</p><p><strong>What surprised me most<br></strong>What surprised me most throughout this project was just how many different combinations the researchers had to test. There were several Cas9 systems and guide RNA combinations, but only one stood out with a particularly strong precise genomic HDR result.</p><p>It made me realise that gene editing isn’t as straightforward as finding a target and cutting the DNA. Even small differences in the editing system can lead to very different outcomes.</p><p>I also found it surprising that, despite the strongest combination performing considerably better than the others, the overall correction frequencies were still relatively low. It showed me how much work is still needed to turn promising laboratory results into something that could eventually help patients.</p><p><strong>What I Took Away From This Project<br></strong>Looking back, this project taught me much more than I expected. I started with an interest in CRISPR, but ended up learning how to read a scientific paper more critically, understand an experimental design, organise published data, and interpret results.</p><p>One of my biggest takeaways was that scientific progress involves a lot of trial and error. Seeing how different CRISPR combinations produced different outcomes helped me appreciate how much experimentation goes into developing a successful gene-editing approach.</p><p>I also learned the importance of questioning data rather than accepting impressive-looking percentages at face value. Understanding what the numbers actually represented completely changed how I interpreted the study.</p><p>Although I didn’t perform laboratory experiments myself, recreating parts of the published research gave me a better understanding of how scientific investigations are analysed and communicated.</p><p>This project has made me even more interested in genetic engineering and the possibility of using gene editing to address inherited diseases. It also reminded me that promising research is only one step towards a real-world solution.</p><p><strong>GitHub repository:</strong><a href="https://github.com/thisistotallynotgyu/CFTR-F508del-CRISPR-Replication?utm_source=chatgpt.com"> </a><a href="https://github.com/thisistotallynotgyu/CFTR-F508del-CRISPR-Replication">https://github.com/thisistotallynotgyu/CFTR-F508del-CRISPR-Replication</a></p><p><strong>Original research paper</strong>:<a href="https://doi.org/10.1371/journal.pone.0242094?utm_source=chatgpt.com"> </a><a href="https://doi.org/10.1371/journal.pone.0242094">https://doi.org/10.1371/journal.pone.0242094</a></p><p><strong>About me:<br></strong>I’m Maya, I’m a high school student passionate about biotechnology, gene therapy, and the future of genetic medicine.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6fff681eb8eb" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Could CRISPR Correct the Genetic Cause of LCA10?]]></title>
            <link>https://medium.com/@mayayazbek469/could-crispr-correct-cep290-mutations-in-lca10-aa1c9ca21dae?source=rss-deffa67e51c6------2</link>
            <guid isPermaLink="false">https://medium.com/p/aa1c9ca21dae</guid>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[crispr]]></category>
            <category><![CDATA[gene-editing]]></category>
            <category><![CDATA[science]]></category>
            <dc:creator><![CDATA[Maya Yazbek]]></dc:creator>
            <pubDate>Tue, 06 Oct 2026 18:48:04 GMT</pubDate>
            <atom:updated>2026-10-26T20:43:51.742Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/800/1*fMJePTjT8vrj0YPAbe8NFw.jpeg" /><figcaption>(MicroOne/Shutterstock)</figcaption></figure><p><strong>The Problem of LCA10.<br></strong>When I stay up late at night and start fantasizing about all the great accomplishments humanity might reach in the future, I reach the “heal it all” part, and I keep wondering how we will ever cure something like genetic blindness. I used to think that something like this would take a miracle. But then I discovered EDIT-101, an experimental gene-editing treatment designed to tackle one of the genetic causes of inherited blindness. It hasn’t become a cure, and there is still a long way to go. Still, the science behind it made me wonder whether some miracles might simply be the result of decades of research.</p><p>To first understand what I mean by any of this, we need to start with our root problem: LCA10.<br>Leber Congenital Amaurosis (LCA10) is a rare inherited retinal disease associated with changes in a gene called CEP290. It can cause severe visual impairment from early childhood, affecting a person’s ability to see and potentially influencing their independence, development, and quality of life. [1]<br>But how can a tiny change in our DNA have such a profound effect on something as complex as vision?</p><p><strong>How One Intronic Change Adds a Cryptic Exon<br></strong>Our bodies rely on genes to provide instructions for making proteins. One of these genes, CEP290, produces a protein important for the normal function of cilia. In retinal photoreceptors, these structures help support the cellular processes required for vision. Disease-causing variants in CEP290 can disrupt photoreceptor function and lead to severe visual impairment. [1]</p><p>The mutation targeted by EDIT-101 is called CEP290 c.2991+1655A&gt;G, also known as IVS26+1655A&gt;G. Although it occurs in an intron — a region normally removed from the RNA message — it creates an abnormal splicing signal. The cell’s RNA-processing machinery mistakenly recognizes this signal and inserts an extra section, called a cryptic exon, into the mature RNA. [2]</p><p>Think of DNA as a cookbook. Before a recipe is used, the cell makes an RNA copy and removes the sections that should not appear in the final instructions. The mutation effectively inserts an unwanted paragraph into that copy. Because the extra sequence contains a premature stop signal, the resulting RNA cannot reliably produce the normal full-length CEP290 protein. The faulty RNA may instead be broken down through a process called nonsense-mediated decay. [2]</p><p>Importantly, the mutation does not necessarily disrupt every RNA transcript. Experimental studies have reported that the abnormal exon is included in roughly half of CEP290 transcripts in certain settings, while other transcripts are spliced normally. This is a context-dependent observation, not a universal percentage for every patient’s retinal cells. [2, 3]</p><p>That distinction matters: the goal is not necessarily to introduce an entirely new gene, but to remove the abnormal splice signal so the cell can produce more correctly processed CEP290 RNA.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/624/0*NiHqOyRGSKq7Dljv.jpg" /><figcaption>Composite fundus image of the right eye of a <em>CEP290</em>-related LCA patient at Age 3. Adapted from “Leber Congenital Amaurosis Due to CEP290 Mutations — Severe Vision Impairment with a High Unmet Medical Need: A Review,” by B. P. Leroy et al., 2021, <em>Retina</em>, 41(5), p. 900. Copyright 2021 by Ophthalmic Communications Society, Inc.</figcaption></figure><p><strong>Potential Treatment Strategies <br></strong>This is where CRISPR enters the picture.</p><p>CRISPR is a gene-editing technology that allows researchers to target particular DNA sequences. One way to understand it is to imagine a molecular editing tool that can be directed to a specific location in the genetic instructions. [4]</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1000/0*LAqIYiKG6nseB4m8.jpg" /><figcaption>(National Human Genome Research Institute [NHGRI], 2026)</figcaption></figure><p>EDIT-101 was developed to use this technology against the CEP290 mutation responsible for this particular form of LCA10.</p><p>But before explaining the editing process, I want to introduce another important idea: delivering the treatment to the right cells.</p><p>A gene-editing tool is not much use if it can’t reach the cells where it is needed. In this case, the target is inside the retina, so the treatment has to deliver its molecular machinery to the relevant retinal cells.</p><p>EDIT-101 uses a modified adeno-associated virus, called AAV5, as a delivery vehicle. The virus is engineered to carry the instructions for the CRISPR components rather than to cause the disease associated with a natural virus. [5, 6]<br>The treatment is administered through a procedure called a subretinal injection, which places it in the space beneath the retina. [5, 6]</p><p>I like to picture the delivery system as an overworked mailman with a very specific destination. The delivery vehicle transports the instructions, and the gene-editing machinery is the tool that acts on the DNA once it reaches the intended cells.</p><p>Of course, the real process is much more complicated than mail delivery. But the analogy helps me separate two different tasks: getting the treatment to the right place and making the intended genetic edit.</p><p><strong>How EDIT-101 Reaches the Retina<br></strong>EDIT-101 uses CRISPR-Cas9, a gene-editing system consisting of the Cas9 DNA-cutting enzyme and two guide RNAs that direct it to specific locations in the CEP290 gene. The treatment is delivered using an engineered adeno-associated virus serotype 5 (AAV5), administered through a subretinal injection to reach the relevant retinal cells. [5, 6]</p><p>Why edit CEP290 instead of replacing it with a working copy? One important reason is the size of the gene’s coding sequence, which makes it difficult to package a complete CEP290 replacement construct into a single conventional AAV vector. EDIT-101 takes a different approach: rather than supplying a new copy of the gene, it attempts to remove the problematic DNA segment already present. [5, 6]</p><p>The process has five main steps:</p><ol><li><strong>Deliver the machinery.</strong> AAV5 transports the instructions for the CRISPR components into targeted retinal cells.</li><li><strong>Locate the mutation.</strong> The two guide RNAs direct Cas9 to DNA sequences on either side of the problematic region.</li><li><strong>Cut and excise.</strong> Cas9 makes cuts at both targeted sites. The cell then repairs the DNA breaks; non-homologous end joining (NHEJ) can join the cut ends together, removing the intervening sequence when repair produces the intended deletion. Repair is not perfectly predictable, however, and not every cell will necessarily receive the desired edit.</li><li><strong>Restore more normal RNA processing.</strong> If the abnormal splice signal is removed successfully, the cell may process CEP290 RNA more normally.</li><li><strong>Potentially improve retinal function.</strong> More normally processed RNA may allow the cell to produce functional CEP290 protein, helping preserve or improve the function of surviving photoreceptors. [5, 6]</li></ol><p>The intended sequence is therefore:</p><p>DNA mutation → abnormal RNA splicing → targeted DNA cuts → repair and excision → more normal RNA processing → potential improvement in visual function.</p><p>The final step is not guaranteed. Delivering the editing machinery, producing the intended DNA change, restoring RNA processing, and improving a patient’s vision are four distinct outcomes that must be evaluated separately.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*AK2m1hqxm0QMrptnziXFzw.png" /><figcaption>(Illustration explaining EDIT-101’s dual-guide CRISPR/Cas9 excision mechanism, generated using OpenAI’s ChatGPT (2026), based on the gene-editing approach described by Maeder et al. (2019), <em>Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10</em>. Nature Medicine, 25, 229–233.<a href="https://doi.org/10.1038/s41591-018-0327-9"> https://doi.org/10.1038/s41591-018-0327-9</a>.)</figcaption></figure><p><strong>The Rationale for CRISPR <br></strong>While researching LCA10, I came across another experimental treatment called QR-110, now known as Sepofarsen. It approaches the problem differently, and comparing the two helped me understand why researchers are exploring multiple ways to treat genetic disease.</p><p>Sepofarsen is an antisense oligonucleotide, or ASO. In simpler terms, it is a short, specially designed strand of genetic material that binds to a target RNA molecule and influences how that message is processed.</p><p>Remember the unwanted paragraph that gets inserted into the CEP290 RNA? Sepofarsen is designed to bind to the RNA near the abnormal splice site, helping the cell’s splicing machinery skip the unwanted section. [3]</p><p>The goal is similar to that of EDIT-101: to allow more normal CEP290 RNA to be produced. But the approach is different.</p><p>Sepofarsen acts on the RNA message, whereas EDIT-101 aims to change the underlying DNA. You could compare the two approaches to correcting a recipe: one helps the cook ignore an incorrect instruction on a working copy, while the other attempts to remove the source of that instruction from the original.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/375/0*WdfviqOkCBcsRZHp.jpg" /><figcaption>(Dulla et al., 2018, Splice-Modulating Oligonucleotide QR-110 Restores CEP290 mRNA and Function in Human c.2991+1655A&gt;G LCA10 Models)</figcaption></figure><p>Neither approach is automatically better in every situation. They have different mechanisms, delivery requirements, risks, and challenges.</p><p><strong>The Clinical Outcomes of Sepofarsen <br></strong>Early studies of sepofarsen produced encouraging observations, including reports of improvements in visual function among some participants. Understandably, these findings raised hopes that the treatment might eventually help people living with LCA10. [3]</p><p>However, promising early results do not always translate into success in a larger trial.<br>In February 2022, ProQR Therapeutics announced that the Phase 2/3 ILLUMINATE study had not met its primary endpoint of best-corrected visual acuity at 12 months. The trial also failed to demonstrate a benefit over the sham-control group on key secondary measures, including retinal light sensitivity and mobility testing. The treatment was generally well tolerated, but the main comparison did not establish the expected clinical benefit. [9]</p><p>I found this disappointing and somewhat frustrating. When you start following a potential treatment for a disease that has few options, it’s easy to become invested in the possibility that it might work. But the ILLUMINATE results reminded me why clinical trials are essential: they help us determine whether a treatment’s promise holds up when it is tested more rigorously.</p><p>The outcome doesn’t mean that every RNA-based approach is futile. It means that the available evidence did not establish Sepofarsen’s benefit in that pivotal trial.</p><p>And that brings us back to EDIT-101. What did researchers actually observe when they tested gene editing in people?</p><p><strong>What BRILLIANCE Actually Showed<br></strong>The BRILLIANCE Phase 1/2 trial evaluated EDIT-101 in 14 participants: 12 adults and two children. Participants received a single subretinal injection in one eye. The trial primarily assessed safety, while changes in visual function were evaluated as secondary outcomes. [7]</p><p>The study tested three dose levels, measured in vector genomes per millilitre (vg/mL):</p><p>-Low dose: (6 × 10¹¹) vg/mL, given to two adults.</p><p>-Intermediate dose: (1 × 10¹²) vg/mL, given to five adults and both children.</p><p>-High dose: (3 × 10¹²) vg/mL, given to five adults. [7]</p><p>No serious adverse events related to the treatment or procedure were reported, and no dose-limiting toxic effects occurred. These findings were encouraging, although a study involving only 14 people cannot rule out uncommon or delayed complications. [7]</p><p>Researchers assessed vision in several ways, rather than relying on a single eye-chart measurement. Best-corrected visual acuity (BCVA) measured how well participants could see with the appropriate correction. Full-field stimulus testing (FST) measured retinal sensitivity to light, including responses associated with cone photoreceptors. The Ora-Visual Navigation Challenge assessed participants’ ability to navigate a course, while questionnaires evaluated vision-related quality of life. [7]</p><p>The numerical results provide a clearer picture of the treatment’s potential:</p><ul><li><strong>Cone-mediated light sensitivity:</strong> Six of 14 participants (43%) improved by at least 0.6 log units in the red-light FST sensitivity threshold, the study’s threshold for a visually meaningful change. Five of these six participants also improved in at least one other key visual-function outcome.</li><li><strong>Visual acuity:</strong> Four of 14 participants (29%) achieved the prespecified threshold for clinically meaningful improvement: at least 0.3 logMAR.</li><li><strong>Mobility:</strong> Four of 14 participants (29%) improved by at least three points on the visual navigation test.</li><li><strong>Combined visual outcomes:</strong> Nine of 14 participants (64%) achieved a meaningful improvement in at least one of three outcomes: visual acuity, red-light sensitivity on FST, or mobility.</li><li><strong>Vision-related quality of life:</strong> Six of 14 participants (43%) improved by at least four points on the relevant questionnaire score. [7]</li></ul><p>These results need careful interpretation. The thresholds describe changes in specific tests; they do not mean that participants recovered normal vision or that the treatment reversed blindness. Some participants improved on more than one measure, so these categories overlap and should not be added together as though they represent different groups of patients.</p><p>The results also do not directly measure how many patients’ DNA was edited successfully. BRILLIANCE assessed safety and clinical outcomes, not the editing rate in patients’ retinal cells. The observed improvements support further investigation of the treatment’s potential, but they do not independently establish the precise biological changes responsible for each participant’s response. [7]</p><p><strong>The short answer:</strong> BRILLIANCE provided encouraging early evidence of safety and improvements in visual function in some participants. The next step is to establish whether these benefits can be reproduced reliably, persist over time, and outweigh the risks in a larger study.</p><p><strong>Why Development Was Paused<br></strong>Despite the encouraging findings, Editas Medicine paused further enrollment in the BRILLIANCE trial and said it would seek a partner to continue development rather than advance the program independently. The small potential treatment population and the limited number of participants showing a clinically meaningful response were important factors in that decision. [8]</p><p>This is an important distinction: the program was not paused simply because the treatment was shown to be unsafe. Rather, the early results suggested that the approach was feasible, but the evidence and the size of the potential responder population did not support the company continuing development alone. [8]</p><p>The study therefore represents an important scientific milestone, not a finished treatment ready for widespread use.</p><p><strong>Remaining Risks and Limitations <br></strong>One challenge is the possibility of off-target editing. CRISPR is designed to target specific DNA sequences, but it can sometimes cut at unintended locations. Depending on where and how the DNA is altered, these changes could disrupt important genes or produce other unwanted effects.</p><p>There are also potential risks associated with unintended changes at the intended target site. DNA repair is a biological process, and it does not always produce exactly the outcome researchers want.</p><p>Delivery creates another set of challenges. The treatment must reach enough of the relevant retinal cells without causing unacceptable harm. The procedure itself carries risks, and the body’s immune system may react to the viral delivery vehicle or the Cas9 protein. Such reactions could reduce the treatment’s effectiveness or cause inflammation.</p><p>Finally, gene editing changes DNA in a way that is intended to be lasting. That makes long-term follow-up especially important. Researchers need to understand not only whether the treatment produces an initial benefit, but also whether that benefit persists and whether unexpected effects emerge over time.<br>These are not reasons to dismiss the technology. They are reasons to test it carefully. [6]</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/750/0*QuEbRtKj7xKgNtUe.jpg" /><figcaption><em>(MicroScience / Shutterstock)</em></figcaption></figure><p><strong>My Prediction for In Vivo Editing in the Eye<br></strong>After researching LCA10 and EDIT-101, I think the biggest obstacle facing in vivo CRISPR gene editing may not be whether it can work in the human eye, but whether it can be developed into a treatment that companies can realistically afford to bring to patients. The BRILLIANCE trial provided encouraging early evidence: Among the 14 participants, 11 showed improvement in at least one of the four key efficacy outcomes, while nine met the prespecified threshold for meaningful improvement in at least one of three measures: visual acuity, red-light sensitivity, or mobility. Six participants also showed meaningful improvement in vision-related quality of life. These findings are encouraging, but improvement on a test does not necessarily mean a patient experienced a substantial improvement in everyday vision. [7]</p><p>The commercial challenge became clear when Editas Medicine paused further enrollment and sought a development partner. The company estimated that only around 300 people in the United States were homozygous for the specific CEP290 variant targeted by EDIT-101. For a treatment requiring specialized manufacturing, retinal surgery, and long-term safety monitoring, such a small potential patient population creates a difficult economic problem. The treatment might work for some patients and still struggle to attract the investment needed to reach them. [8]</p><p>The failure of Sepofarsen to meet its primary endpoint in the Phase 2/3 ILLUMINATE trial adds another reason for caution. That result does not prove RNA-based treatments cannot work, just as the BRILLIANCE findings do not prove that DNA editing will ultimately succeed. The two approaches differ in their mechanisms, and neither early promise nor a disappointing trial result should be treated as the final word on an entire technology. [9]</p><p>There is a strong counterargument to my prediction. EDIT-101 attempts to address the underlying DNA mutation, potentially producing a lasting effect after a single treatment rather than requiring repeated intervention. If future studies confirm durable improvements in vision, identify the patients most likely to benefit, and demonstrate an acceptable long-term safety profile, those advantages could make the treatment attractive to a pharmaceutical partner. A larger development program could also benefit from improved delivery methods and advances in gene-editing technology.</p><p>What would change my mind? I would become much more optimistic if a larger, well-designed clinical trial showed that EDIT-101 consistently improved visual function compared with an appropriate control, with benefits that persisted over several years. Evidence that a development partner could manufacture and deliver the treatment sustainably would also weaken my concern about its commercial future.</p><p>For now, my prediction is that the future of in vivo CRISPR for LCA10 will depend as much on economics and patient selection as on molecular biology. BRILLIANCE showed that editing DNA inside the living human eye is possible to attempt and can be accompanied by improvements in visual function. It did not establish that EDIT-101 is a cure, nor did it demonstrate the rate of successful DNA editing in patients. The next challenge is turning a promising proof of concept into a treatment that is safe, effective, durable, and accessible.</p><p>I still find that possibility remarkable. We may not be able to “heal it all,” but research into EDIT-101 shows how decades of work can bring an idea once confined to the laboratory into human clinical testing. To me, that is exciting enough without calling it a miracle. The real breakthrough will be when the science not only works, but reaches the people who need it.</p><p><strong>References:</strong></p><p>[1] Leroy, B. P., et al. (2021). “Leber Congenital Amaurosis Due to CEP290 Mutations — Severe Vision Impairment with a High Unmet Medical Need: A Review.” *Retina, 41*(5). <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8078118/">https://pmc.ncbi.nlm.nih.gov/articles/PMC8078118/</a></p><p>[2] Garanto, A., Duijkers, L., &amp; Collin, R. W. J. (2015). “Species-Dependent Splice Recognition of a Cryptic Exon Resulting from a Recurrent Intronic CEP290 Mutation that Causes Congenital Blindness.” *International Journal of Molecular Sciences, 16*(3), 5285–5298. <a href="https://doi.org/10.3390/ijms16035285">https://doi.org/10.3390/ijms16035285</a></p><p>[3] Dulla, K., Slijkerman, R., van Diepen, H. C., et al. (2018). “Splice-Modulating Oligonucleotide QR-110 Restores CEP290 mRNA and Function in Human c.2991+1655A&gt;G LCA10 Models.” *Molecular Therapy — Nucleic Acids, 12*, 730–740. <a href="https://doi.org/10.1016/j.omtn.2018.07.010">https://doi.org/10.1016/j.omtn.2018.07.010</a></p><p>[4] National Human Genome Research Institute. “CRISPR.” <a href="https://www.genome.gov/genetics-glossary/CRISPR">https://www.genome.gov/genetics-glossary/CRISPR</a></p><p>[5] Maeder, M. L., Stefanidakis, M., Wilson, C. J., et al. (2019). “Development of a Gene-Editing Approach to Restore Vision Loss in Leber Congenital Amaurosis Type 10.” *Nature Medicine, 25*, 229–233. <a href="https://doi.org/10.1038/s41591-018-0327-9">https://doi.org/10.1038/s41591-018-0327-9</a></p><p>[6] Ling, J., Jenny, L. A., Zhou, A., &amp; Tsang, S. H. (2023). “Therapeutic Gene Editing in Inherited Retinal Disorders.” *Cold Spring Harbor Perspectives in Medicine, 13*(4), a041292. <a href="https://doi.org/10.1101/cshperspect.a041292">https://doi.org/10.1101/cshperspect.a041292</a></p><p>[7] Pierce, E. A., et al. (2024). “Gene Editing for CEP290-Associated Retinal Degeneration.” *New England Journal of Medicine, 390*, 1972–1984. <a href="https://doi.org/10.1056/NEJMoa2309915">https://doi.org/10.1056/NEJMoa2309915</a></p><p>[8] Editas Medicine. (2022, November 17). “Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial.” <a href="https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-clinical-data-demonstrating-proof">https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-clinical-data-demonstrating-proof</a></p><p>[9] ProQR Therapeutics. (2022, February 11). “ProQR Announces Top-Line Results from Phase 2/3 ILLUMINATE Trial of Sepofarsen in CEP290-Mediated LCA10.” <a href="https://www.proqr.com/press-releases/proqr-announces-top-line-results-from-phase-23-illuminate-trial-of-sepofarsen-in-cep290-mediated-lca10">https://www.proqr.com/press-releases/proqr-announces-top-line-results-from-phase-23-illuminate-trial-of-sepofarsen-in-cep290-mediated-lca10</a></p><p><strong>About Me:</strong> <br>I’m Maya, I’m a high school student passionate about biotechnology, gene therapy, and the future of genetic medicine.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=aa1c9ca21dae" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>